Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Mar;276(1):5-8.
doi: 10.1111/imr.12531.

Introduction to checkpoint inhibitors and cancer immunotherapy

Arlene H Sharpe  1
Affiliations

Introduction to checkpoint inhibitors and cancer immunotherapy

Arlene H Sharpe. Immunol Rev. 2017 Mar.
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1. Overview of innate and adaptive checkpoint pathways
Innate immune cells express checkpoint molecules that regulate their functions. Inhibitory checkpoint molecules (e.g. TAM receptors, Siglecs, CD47) expressed by innate immune cells inhibit their activity and limit adaptive immunity. Adaptive checkpoint molecules regulate T cell responses. Activation of naive T cells is mediated by TCR recognition of antigen presented on APCs and costimulatory signals provided by CD28 interactions with CD80 and CD86. Upon T cell activation, a second tier of costimulatory pathways is upregulated. There also are many inhibitory checkpoint receptors that are upregulated on T cells and inhibit T cell responses. Their ligands can be expressed by APCs, non-hematopoietic cells, and tumors. Binding partners for B7-H3, B7-H4, VISTA are not yet known. Several receptors have multiple binding partners.
See this image and copyright information in PMC

References

    1. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711–723. - PMC - PubMed
    1. McDermott DF, Drake CG, Sznol M, Choueiri TK, Powderly JD, Smith DC, Brahmer JR, Carvajal RD, Hammers HJ, Puzanov I, et al. Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab. J Clin Oncol. 2015;33:2013–2020. - PMC - PubMed
    1. Ribas A, Puzanov I, Dummer R, Schadendorf D, Hamid O, Robert C, Hodi FS, Schachter J, Pavlick AC, Lewis KD, et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol. 2015;16:908–918. - PMC - PubMed
    1. Schadendorf D, Hodi FS, Robert C, Weber JS, Margolin K, Hamid O, Patt D, Chen TT, Berman DM, Wolchok JD. Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma. J Clin Oncol. 2015;33:1889–1894. - PMC - PubMed
    1. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366:2443–2454. - PMC - PubMed

Publication types

Substances